share_log

Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying

Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying

Vivani医疗和其他2只低于2美元的股票内部人员正在购买
Benzinga ·  08/02 07:41

The Dow Jones index closed lower by around 500 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道琼斯指数周四收跌约500点。当内部人员买卖股票时,意味着他们对公司前景的信心或担忧。对于有兴趣购买低价股的投资者和交易员来说,可以将此视为他们整体投资或交易决策的一个因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是几个近期关于低价股的值得关注的内部交易。了解更多,请查看Benzinga内幕交易平台。

Cyanotech

赛安诺科技

  • The Trade: Cyanotech Corporation (OTC:CYAN) Director Michael A / Davis bought a total of 10,000 shares at an average price of $0.77. To acquire these shares, it cost around $7,700.
  • What's Happening: On June 26, Cyanotech reported net sales of $23,071,000 for fiscal 2024 compared to $23,178,000 in fiscal 2023.
  • What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market.
  • 交易:赛安诺科技公司(OTC:CYAN)董事Michael A / Davis以平均价格0.77美元购买了总计1万股。购买这些股票花费了约7700美元。
  • 近况:6月26日,Cyanotech报告称,2024财年净销售额为2,307.1万美元,而2023财年为2,317.8万美元。
  • 赛安诺科技公司从微藻中提炼可用于营养补充剂市场的天然产品。

RENN Fund

renn fund

  • The Trade: RENN Fund, Inc. (NYSE:RCG) President and CEO Murray Stahl acquired a total of 1,164 shares at an average price of $1.79. To acquire these shares, it cost around $2,084.
  • What's Happening: RENN Fund shares gained around 7% over the past six months.
  • What RENN Fund Does: RENN Fund Inc is active in the financial services domain.
  • 交易:renn fund (NYSE:RCG)总裁兼首席执行官Murray Stahl以平均价格1.79美元购买了总计1164股。购买这些股票花费了约2084美元。
  • RENNS Fund股价在过去六个月内上涨了约7%。
  • RENNS Fund Inc在金融服务领域活跃。

Vivani Medical

Vivani 医疗

  • The Trade: Vivani Medical, Inc. (NASDAQ:VANI) Chief Business Officer Donald Dwyer acquired a total of 9,000 shares at an average price of $1.24. The insider spent around $11,120 to buy those shares. He also purchased 2,000 shares at $0.96.
  • What's Happening: Vivani Medical expects to initiate the first clinical study for the NPM-115 program in Australia in the fourth quarter of 2024.
  • What Vivani Medical Does: Vivani Medical Inc is a preclinical-stage biopharmaceutical company.
  • 交易:Vivani Medical, Inc. (NASDAQ:VANI)首席商务官Donald Dwyer以平均价格1.24美元购买了总计9000股。内部人员花费大约11,120美元购买了这些股票。他还以0.96美元购买了2000股。
  • 最新进展:Vivani Medical公司预计将于2024年第四季度在澳洲开始NPm-115项目的第一项临床研究。
  • Vivani Medical Inc是一家处于临床前阶段的生物制药公司。
  • Amazon, Apple And 3 Stocks To Watch Heading Into Friday
  • 周五关注的亚马逊、苹果和3只股票
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发